OBI Pharma (ROCO:4174) Payments of Debt: NT$-157.89 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4174 OBI Pharma Inc ROCO:4174
26 GF Score
Price NT$25.10
! 8 Warning Signs
View Full Analysis

What is OBI Pharma Payments of Debt?

OBI Pharma ROCO:4174 +0.80% 26 Payments of Debt is NT$-157.89 Mil as of Mar. 2026. GuruFocus rates ROCO:4174 with a GF Score™ of 26/100. The stock has 8 warning signs investors should review.

OBI Pharma's Payments of Debt for the three months ended in Mar. 2026 was NT$-46.02 Mil.

OBI Pharma's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was NT$-157.89 Mil.

OBI Pharma Payments of Debt Related Terms

OBI Pharma Payments of Debt Historical Data

* Premium members only.

The historical data trend for OBI Pharma's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OBI Pharma Payments of Debt Chart

OBI Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.47 -7.00 -18.40 -42.99 -120.40

OBI Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.52 -11.97 -47.33 -52.57 -46.02
ROCO:4174
26GF Score
OBI Pharma Inc ROCO:4174
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OBI Pharma Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-157.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of NT$-157.89 Mil mean?
OBI Pharma (ROCO:4174) has a Payments of Debt of NT$-157.89 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on OBI Pharma and its competitors.
Is OBI Pharma's Payments of Debt too high?
OBI Pharma's current Payments of Debt is NT$-157.89 Mil. Overall, OBI Pharma has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does OBI Pharma's Payments of Debt compare to VRTX and REGN?
OBI Pharma's Payments of Debt of NT$-157.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on OBI Pharma and its competitors. OBI Pharma's current Payments of Debt is NT$-157.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OBI Pharma stock overvalued right now?
OBI Pharma (ROCO:4174) has a current Payments of Debt of NT$-157.89 Mil. The current Payments of Debt is NT$-157.89 Mil. OBI Pharma's overall GF Score™ is 26/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For OBI Pharma (ROCO:4174), the current Payments of Debt is NT$-157.89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OBI Pharma Business Description

Address Zhongxiao East Road, 6th Floor, No. 508, Section 7, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
26GF Score

Get the complete analysis for ROCO:4174

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.10
Price